The IL1R1 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the LoVo human colorectal adenocarcinoma cell line, with targeted disruption of the IL1R1 gene. This heterogeneous pool of IL1R1 loss-of-function cells retains genetic diversity suitable for bulk functional assays without clonal artifacts, enabling study of interleukin-1 receptor type 1 (IL-1R1) signaling in cancer.
The parental LoVo line, established from a metastatic colon adenocarcinoma of a human male, is a widely utilized epithelial model in colorectal cancer research. LoVo cells exhibit rapid proliferation and invasive properties, and they naturally express functional IL1R1, capable of responding to IL-1 stimulation by activating pro-inflammatory signaling cascades. This makes them a clinically relevant system for studying IL-1-driven tumor progression.
IL1R1 encodes the receptor for the pro-inflammatory cytokines IL-1?? and IL-1??. Upon ligand binding, IL1R1 recruits the co-receptor IL1RAP and the adaptor MYD88, which triggers the sequential activation of IRAK4 and IRAK1, leading to TRAF6-mediated activation of the IKK complex. This results in phosphorylation and degradation of I??B, allowing NF-??B nuclear translocation and transcription of target genes. Concurrently, MAPK pathway activation leads to AP-1-mediated gene expression. Key downstream targets include IL6, CXCL8 (IL8), and matrix metalloproteinases, which drive inflammation and tissue remodeling. In these polyclonal knockout cells, disruption of IL1R1 abrogates ligand binding and downstream signaling, preventing the induction of these pro-inflammatory mediators.
In colorectal cancer, IL-1 signaling is often upregulated and associated with a pro-tumorigenic microenvironment, promoting angiogenesis, invasion, and immune evasion. The IL1R1 Knockout LoVo Polyclonal Cells thus provide a powerful tool to investigate the consequences of lost IL-1 responsiveness. By comparing knockout with parental cells, researchers can dissect the contributions of IL-1R1 to tumor cell-autonomous behaviors (proliferation, migration) and paracrine signaling that influences stromal and immune cells. This model is particularly relevant for inflammation-linked colorectal cancer research, where IL-1 has been implicated in adenoma-to-carcinoma progression and metastasis.
These polyclonal knockout cells are suitable for a wide range of experimental applications. They can be employed in Western blotting and RT-qPCR to verify the absence of IL1R1 protein and mRNA, and to measure changes in downstream signaling molecules such as phosphorylated I??B and NF-??B. NF-??B reporter assays and cytokine secretion ELISAs (e.g., for IL-6 and CXCL8) allow quantitative assessment of pathway activity. Functional assays, including proliferation, migration, and invasion studies, reveal phenotypic consequences of IL1R1 loss. Co-culture systems with macrophages or T cells enable investigation of tumor-immune crosstalk. The model also supports drug screening for IL-1 antagonists. For further technical information, please contact Ascent Research.
